I’m convinced, and I know most of you are too, that we will not get to a complete understanding of diseases and biology in general without looking behind a multi-omics lens. While NGS radically democratized access to genomics information with RNA-seq, for example, the complexity of other assays like ChIP-seq and the ensuing challenges in combining different types of data analyses have limited the wide scale adoption of multi-omics approaches.
Recent posts by Jean Lozach
3 min read
2 min read
Schistosoma mansoni causes schistosomiasis, a disease of poverty that infects approximately 200 million people worldwide. Treatment of the disease relies on praziquantel (PZQ). With the expanding use of the drug, there is a fear over the development of resistance. It is, therefore, important to discover new drugs and drug targets.
I'm really happy to announce another poster and research project utilizing ROSALIND, our analysis and collaboration platform for genomics.
Topics: BioInformatics Rosalind RNAseq Collaboration UCSD
2 min read
OnRamp takes home the "People's Choice - Best of Show" award at BioIT-World 2018 in Boston.
4 min read
As proud contender for Bio-IT World's "People's Choice - Best in Show", ROSALIND will have latest features presented throughout the event
Event: Bio-IT World
Dates: 5/15/18 - 5/17/18
Location: Seaport World Trade Center, Boston MA
Event URL: www.bio-itworld.com/
1 min read
OnRamp's CEO, Tim Wesselman, features ROSALIND™ during Plenary Keynote Panel on Emerging Technologies and Industry Perspectives
Event: Molecular Medicine Tri-Conference
Date/Time: February 14th @ 8:45a PT
Location: San Francisco Moscone Convertion Hall
Event URL: http://www.triconference.com/
1 min read
Our mission is to transform how cancer researchers and biologists analyze their data (at SCALE)!
Advanced bioinformaticians deserve all of the credit for building state-of-the-art applications to analyze genomic, proteomic, and microarray data. While these tools remain the lifeline of genomic analysis, more simplified user experiences are now required to empower today’s cancer biologists to focus on their research application, not which software application to use.